Target

IL-15

Interleukin-15

28open trials
43trials in total
59publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
30 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
11 Nov 2026· PHASE2 · RECRUITING· CTGOV
Publication
IL-15/IL-15Rα-targeted CRISPRa boosts NK cell effector function against HIV-infected cells.
5 Nov 2026· Journal of leukocyte biology· PUBMED
Publication
Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.
3 Nov 2026· Nature medicine· PUBMED
Trial
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Opposing Natural Killer and Macrophage Associations Are Masked Within a CD16/IL-15/IL-15RA Composite Score in Metastatic Urothelial Carcinoma.
9 Oct 2026· International journal of molecular sciences· PUBMED
Preprint
Restoration of deficient IL-15 signaling enhances innate lymphoid cell immunity in brain metastasis.
9 Oct 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Metabolic Rewiring of GPC3-Targeted CAR T Cells Expressing IL-15 and HER2-Targeted CAR T Cells via the ADA1-CD26 Axis Promotes Tumor Infiltration and Limits Systemic Toxicities.
6 Oct 2026· Biomedicines· PUBMED
Publication
IL-15 drives antigen-independent increase in granzyme K+B+ CD8 T cells enriched in rheumatoid arthritis joints.
4 Oct 2026· Journal of autoimmunity· PUBMED
Trial
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
1 Oct 2026· PHASE2 · RECRUITING· CTGOV
Publication
IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.
22 Sept 2026· Oncoimmunology· PUBMED
Publication
Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity.
16 Sept 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
Chimeric IL-15 as a next-generation immunotherapeutic: preclinical assessment of efficacy and safety.
2 Sept 2026· International immunopharmacology· PUBMED
Trial
GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)
1 Sept 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
1 Sept 2026· PHASE2 · RECRUITING· CTGOV
Publication
Intestinal flagellin drives multisystem inflammation through TLR5-IL-15-ARA axis.
19 Aug 2026· Gut· PUBMED
Publication
Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity.
14 Aug 2026· Journal of virology· PUBMED
Trial
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
11 Aug 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
IL-15 superagonists for reprogramming the immunosuppressive microenvironment in gastrointestinal adenocarcinomas.
11 Aug 2026· Cancer letters· PUBMED
Publication
IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.
5 Aug 2026· Molecular therapy. Oncology· PUBMED
Publication
Trans-Presentation of IL-15 by IL15Rα Attenuates Tumor Immune Surveillance and Is Dispensable for IL-15-Dependent Tumor Growth Control.
4 Aug 2026· Cancers· PUBMED
Publication
Development of HPV nanovaccine candidate based on IL-15-E7 fusion protein encapsulated in silk-fibroin nanoparticles.
25 Jul 2026· International journal of pharmaceutics· PUBMED
Publication
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.
24 Jul 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Methodological Considerations in Interpreting IL-15 Plus Thymosin α1 Therapy for Hepatocellular Carcinoma.
17 Jul 2026· Journal of gastroenterology and hepatology· PUBMED
Publication
Comments on IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
16 Jul 2026· Journal of gastroenterology and hepatology· PUBMED
Trial
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
7 Jul 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
An IL-15 fusion with albumin-binding domain boosts immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1/2.
4 Jul 2026· Cancer letters· PUBMED
Publication
Spatial profiling of tissue-resident memory T cells reveals stromal IL-15 niches and a paradoxical CD103⁺ phenotype predicting survival in oral squamous cell carcinoma.
3 Jul 2026· BMC cancer· PUBMED
Publication
Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.
3 Jul 2026· Journal for immunotherapy of cancer· PUBMED
Trial
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
29 May 2026· PHASE3 · WITHDRAWN· CTGOV

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error